Novel AAV843 Vector-Mediated Gene Replacement Therapy Rescues Primary Hyperoxaluria Type I in Mice
Cells · 31.03.2026 · 15 (7) · 629
DOI: 10.3390/cells15070629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 31.03.2026. Verfasst von Jingjia Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China. Hauptthemen laut MEDLINE: Hyperoxaluria, Primary, Genetic Therapy, Dependovirus, Genetic Vectors. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Shanghai Municipal Science and Technology Commission.
Abstract (Originalsprache)
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder resulting from mutations in the alanine–glyoxylate aminotransferase (AGXT) gene, leading to excessive systemic deposition of calcium oxalate. This condition is an important cause of end-stage renal disease in children and poses a serious threat to patient survival. Current therapeutic approaches are limited primarily to conservative management and organ transplantation, underscoring the need for more effective treatments. Gene replacement therapy represents a promising alternative strategy. In this study, Agxt−/− mice lacking exons 3–8 were characterized, confirming the complete loss of hepatic alanine–glyoxylate aminotransferase (AGT) expression and the presence of early-onset hyperoxaluria. Exposure to glyoxylic acid induced pronounced renal calcium oxalate crystal deposition, establishing a robust and previously unreported induction approach in gene-edited PH1 mouse models. Using this platform, human AGXT cDNA was delivered via the liver-tropic, low-immunogenic AAV843 vector, which has been employed in clinical trials for hemophilia. Gene therapy resulted in normalization of urinary oxalate levels, restoration of hepatic AGT expression, and significant attenuation of renal injury and nephrocalcinosis. These therapeutic effects were accompanied by significant suppression of key mediators involved in renal inflammation, necroptosis, and fibrosis. Moreover, transgene expression was highly specific to the liver and was not associated with hepatotoxicity. These results demonstrate that AAV843-mediated AGXT gene replacement is a safe and effective approach that achieves phenotypic correction in a murine model of PH1, warranting further evaluation in preclinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China.
- Shanghai Kidney Development & Pediatric Kidney Disease Research Center, Shanghai 201100, China.
- Institute of Developmental Biology and Molecular Medicine, Fudan University, Shanghai 200438, China.
- School of Biotechnology, East China University of Science and Technology, Shanghai 200237, China.
- School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
- National Key Laboratory of Kidney Diseases, Beijing 100853, China.
ORCID-Profile: Qian Shen
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- Shanghai Municipal Science and Technology Commission
- National Key R&D Program of China
- National Natural Science Foundation
- Shanghai Municipal Science and Technology
Zitieren
APA
Zhang, J., Yin, Y., Ji, B., Sun, M., Jiang, Y., Wu, X., Xiao, X., Shen, Q., Wu, X., & Xu, H. (2026). Novel AAV843 Vector-Mediated Gene Replacement Therapy Rescues Primary Hyperoxaluria Type I in Mice. Cells, 15(7), 629. https://doi.org/10.3390/cells15070629
Vancouver
Zhang J, Yin Y, Ji B, Sun M, Jiang Y, Wu X, et al. Novel AAV843 Vector-Mediated Gene Replacement Therapy Rescues Primary Hyperoxaluria Type I in Mice. Cells. 2026;15(7):629. doi:10.3390/cells15070629
BibTeX
@article{Zhang2026,
author = {Zhang, Jingjia and Yin, Ye and Ji, Baowei and Sun, Manqing and Jiang, Yuanyan and Wu, Xiaohui and Xiao, Xiao and Shen, Qian and Wu, Xia and Xu, Hong},
title = {Novel AAV843 Vector-Mediated Gene Replacement Therapy Rescues Primary Hyperoxaluria Type I in Mice},
journal = {Cells},
year = {2026},
volume = {15},
number = {7},
pages = {629},
doi = {10.3390/cells15070629}
}
EUVIMED